MEDICAL ONCOLOGY

OPEN TO RECRUITMENT — AUSTRALIA & NEW ZEALAND

Abbrev. Title

Protocol Title iTestis WEHI Bioinformatics for Testis Cancer Database

KRAB Kidney Cancer Australian Registry and Biobank

LM108-01-101

A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination with Anti-PD-1 Antibody in Subjects with Advanced Solid Tumours

MASC 03.18 I-MAT

A Randomised Placebo-Controlled Phase II Trial of Adjuvant Avelumab in Early Stage Merkel Cell Carcinoma

MAX-10181-001

A Phase I Study of MAX-10181 Given Orally to Patients with Advanced Solid Tumour

MER-XMT-1536-1 UP-LIFT A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumours Likely to Express NaPi2b

MER-XMT-1536-3 UPNEXT A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent, Platinum-Sensitive, Ovarian Cancer

MG010-001 SUCCEED A Phase II, Two-Arm, Open Label, Randomised, Multi-Centre Study to Assess the Safety, Tolerability and Efficacy of MG010 in Combination with Sorafenib in Subjects with Solid Tumours who Have Failed Existing Treatments

MK-3475-867

Keynote-867

MK-7684A-006

Keyvibe-006

A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK3475) in Participants With Unresected Stages I or II Non Small Cell Lung Cancer

Open Label Phase 3 Study MK7684A (Coformulation of MK-7684 200mg and Pembrolizumab 200 mg) in Combination with CCRT followed by MK7684A Vs CCRT followed by Durvalumab in Participants with Unresectable, Locally-Advanced, Stage III NSCLC (All-Comers Regardless of PD-L1 Status)